Gestala Secures Record $21M Angel Round to Pioneer Non-Invasive Ultrasound Brain Interfaces

Gestala Technology Co., Ltd. has announced the completion of a massive 150 million RMB (approximately $21.6 million USD) Angel Round funding. This milestone comes just two months after the company's official launch in January 2026. The investment marks the largest early-stage financing event in the history of China's brain-computer interface industry. The funding round was co-led by Guosheng Capital and Daotong Investment, signaling strong institutional confidence in non-invasive neural technology. Additional backing came from a diverse group of investors including Qingsong Capital, Gobi Partners, Liepin, and Yunshi Capital. Notably, robotic specialist Fourier Intelligence also participated, following a recent strategic partnership between the two firms. Based in Chengdu, Gestala focuses on low-intensity focused ultrasound to interact with the human brain without the need for surgical implants. This "third door" approach allows for high-precision neuromodulation and brain signaling at depths of up to seven centimeters. By converting sound waves into bio-electrical signals, the platform can target deep areas like the thalamus and hippocampus.

The startup was co-founded by CEO Phoenix Peng, a veteran entrepreneur, and Chen Tianqiao, the philanthropist behind the Shanda Group. Their mission centers on creating a future where humanity is free from brain-related diseases through AI co-evolution. The company currently operates R&D centers across Chengdu, Shanghai, and Hong Kong to accelerate these goals.

Capital from this round is earmarked for the research and development of first-generation medical devices and the establishment of mass-production lines by late 2026. Gestala is currently prioritizing clinical trials for chronic pain management, with preliminary results showing a significant reduction in patient pain scales. Future applications are expected to include stroke rehabilitation and PTSD treatment. This rapid financial growth coincides with favorable policy shifts, as BCI technology was recently included in the Chinese Government Work Report. As global competition intensifies with companies like Merge Labs in the United States, Gestala's recent surge positions it as a frontrunner in the Asian market. The company aims to commercialize its first therapeutic devices as early as 2027.